nodes	percent_of_prediction	percent_of_DWPC	metapath
Etomidate—SLC2A1—HIF-2-alpha transcription factor network—CITED2—bone cancer	0.164	0.165	CbGpPWpGaD
Etomidate—SLC2A1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.0966	0.0972	CbGpPWpGaD
Etomidate—CYP11B2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0538	0.0541	CbGpPWpGaD
Etomidate—CYP11B1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0464	0.0467	CbGpPWpGaD
Etomidate—SLC2A1—Validated targets of C-MYC transcriptional activation—BMI1—bone cancer	0.0374	0.0376	CbGpPWpGaD
Etomidate—SLC2A1—Glycolysis and Gluconeogenesis—ENO2—bone cancer	0.0308	0.031	CbGpPWpGaD
Etomidate—CYP19A1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0263	0.0264	CbGpPWpGaD
Etomidate—CYP11B2—Metapathway biotransformation—CYP4V2—bone cancer	0.0232	0.0233	CbGpPWpGaD
Etomidate—SLC2A1—Validated targets of C-MYC transcriptional activation—EIF2S1—bone cancer	0.0209	0.021	CbGpPWpGaD
Etomidate—CYP11B1—Metapathway biotransformation—CYP4V2—bone cancer	0.02	0.0201	CbGpPWpGaD
Etomidate—SLC2A1—Regulation of insulin secretion—GNA11—bone cancer	0.0186	0.0187	CbGpPWpGaD
Etomidate—SLC2A1—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.0181	0.0182	CbGpPWpGaD
Etomidate—SLC2A1—Integration of energy metabolism—GNA11—bone cancer	0.0146	0.0147	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—FEV—bone cancer	0.0117	0.0118	CbGpPWpGaD
Etomidate—CYP19A1—Metapathway biotransformation—CYP4V2—bone cancer	0.0113	0.0114	CbGpPWpGaD
Etomidate—CYP11B2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.0108	0.0108	CbGpPWpGaD
Etomidate—CYP11B2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.0106	0.0107	CbGpPWpGaD
Etomidate—SLC2A1—Validated targets of C-MYC transcriptional activation—CDK4—bone cancer	0.0103	0.0103	CbGpPWpGaD
Etomidate—CYP11B1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00929	0.00935	CbGpPWpGaD
Etomidate—CYP11B1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00917	0.00923	CbGpPWpGaD
Etomidate—CYP11B2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00874	0.0088	CbGpPWpGaD
Etomidate—SLC2A1—NRF2 pathway—TGFBR2—bone cancer	0.00866	0.00871	CbGpPWpGaD
Etomidate—SLC2A1—NRF2 pathway—GSTP1—bone cancer	0.00866	0.00871	CbGpPWpGaD
Etomidate—GABRB2—Orphan transporters—TUBB4B—bone cancer	0.00841	0.00846	CbGpPWpGaD
Etomidate—SLC2A1—Carbohydrate metabolism—ENO2—bone cancer	0.00814	0.00819	CbGpPWpGaD
Etomidate—GABRG2—Orphan transporters—TUBB4B—bone cancer	0.00769	0.00774	CbGpPWpGaD
Etomidate—SLC2A1—HIF-1-alpha transcription factor network—JUN—bone cancer	0.00763	0.00768	CbGpPWpGaD
Etomidate—SLC2A1—Insulin Signaling—IGF1R—bone cancer	0.00757	0.00762	CbGpPWpGaD
Etomidate—CYP11B1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00753	0.00758	CbGpPWpGaD
Etomidate—CYP11B1—Corticotropin-releasing hormone—GNA11—bone cancer	0.00728	0.00733	CbGpPWpGaD
Etomidate—GABRB2—Orphan transporters—TUBB2A—bone cancer	0.00726	0.00731	CbGpPWpGaD
Etomidate—SLC2A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00681	0.00685	CbGpPWpGaD
Etomidate—SLC2A1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	0.00679	0.00683	CbGpPWpGaD
Etomidate—GABRA1—Orphan transporters—TUBB4B—bone cancer	0.00672	0.00677	CbGpPWpGaD
Etomidate—GABRG2—Orphan transporters—TUBB2A—bone cancer	0.00664	0.00668	CbGpPWpGaD
Etomidate—CYP19A1—Tryptophan metabolism—CYP3A4—bone cancer	0.00651	0.00655	CbGpPWpGaD
Etomidate—SLC2A1—Validated targets of C-MYC transcriptional activation—MMP9—bone cancer	0.00643	0.00647	CbGpPWpGaD
Etomidate—SLC2A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00588	0.00591	CbGpPWpGaD
Etomidate—GABRA1—Orphan transporters—TUBB2A—bone cancer	0.0058	0.00584	CbGpPWpGaD
Etomidate—CYP19A1—Ovarian Infertility Genes—CDK4—bone cancer	0.0054	0.00543	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—NDUFA12—bone cancer	0.00532	0.00535	CbGpPWpGaD
Etomidate—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00527	0.0053	CbGpPWpGaD
Etomidate—CYP19A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.0052	0.00523	CbGpPWpGaD
Etomidate—CYP11B2—Biological oxidations—CYP3A4—bone cancer	0.00464	0.00467	CbGpPWpGaD
Etomidate—CYP11B2—Metapathway biotransformation—CYP3A4—bone cancer	0.00458	0.00461	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—NT5C3A—bone cancer	0.00441	0.00444	CbGpPWpGaD
Etomidate—SLC2A1—Validated targets of C-MYC transcriptional activation—TP53—bone cancer	0.00436	0.00439	CbGpPWpGaD
Etomidate—CYP19A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00427	0.0043	CbGpPWpGaD
Etomidate—CYP11B1—Biological oxidations—CYP3A4—bone cancer	0.004	0.00403	CbGpPWpGaD
Etomidate—CYP11B2—Biological oxidations—GSTP1—bone cancer	0.00397	0.004	CbGpPWpGaD
Etomidate—CYP11B1—Metapathway biotransformation—CYP3A4—bone cancer	0.00395	0.00397	CbGpPWpGaD
Etomidate—CYP11B2—Metapathway biotransformation—GSTP1—bone cancer	0.00392	0.00394	CbGpPWpGaD
Etomidate—SLC2A1—Insulin Signaling—JUN—bone cancer	0.00376	0.00378	CbGpPWpGaD
Etomidate—CYP11B1—Corticotropin-releasing hormone—BRAF—bone cancer	0.00362	0.00364	CbGpPWpGaD
Etomidate—Fenoprofen—PTGS2—bone cancer	0.00356	0.565	CrCbGaD
Etomidate—CYP11B1—Biological oxidations—GSTP1—bone cancer	0.00342	0.00344	CbGpPWpGaD
Etomidate—CYP11B1—Metapathway biotransformation—GSTP1—bone cancer	0.00337	0.0034	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (i) signalling events—GRM4—bone cancer	0.00315	0.00317	CbGpPWpGaD
Etomidate—ADRA2B—G alpha (i) signalling events—RGS1—bone cancer	0.00315	0.00317	CbGpPWpGaD
Etomidate—CYP19A1—Tryptophan metabolism—MDM2—bone cancer	0.00299	0.00301	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—NDUFA12—bone cancer	0.00278	0.0028	CbGpPWpGaD
Etomidate—Pethidine—CYP3A4—bone cancer	0.00274	0.435	CrCbGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.00258	0.0026	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.00248	0.0025	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—NDUFA12—bone cancer	0.0024	0.00241	CbGpPWpGaD
Etomidate—SLC2A1—Disease—ENO2—bone cancer	0.00231	0.00232	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—NT5C3A—bone cancer	0.00231	0.00232	CbGpPWpGaD
Etomidate—CYP19A1—Biological oxidations—CYP3A4—bone cancer	0.00227	0.00228	CbGpPWpGaD
Etomidate—CYP19A1—Metapathway biotransformation—CYP3A4—bone cancer	0.00224	0.00225	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.00215	0.00217	CbGpPWpGaD
Etomidate—SLC2A1—Disease—DHFR—bone cancer	0.00214	0.00215	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.0021	0.00212	CbGpPWpGaD
Etomidate—GABRB2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00205	0.00207	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.00202	0.00203	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—NT5C3A—bone cancer	0.00199	0.002	CbGpPWpGaD
Etomidate—CYP19A1—Biological oxidations—GSTP1—bone cancer	0.00194	0.00195	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—ENO2—bone cancer	0.00193	0.00194	CbGpPWpGaD
Etomidate—CYP19A1—Metapathway biotransformation—GSTP1—bone cancer	0.00191	0.00192	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—GRM4—bone cancer	0.00191	0.00192	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00188	0.00189	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.00185	0.00186	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—DHFR—bone cancer	0.00179	0.0018	CbGpPWpGaD
Etomidate—GABRB2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00177	0.00178	CbGpPWpGaD
Etomidate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00173	0.00174	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—IL3—bone cancer	0.00168	0.00169	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—GNA11—bone cancer	0.00167	0.00169	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—GRM1—bone cancer	0.00165	0.00166	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00164	0.00165	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00162	0.00163	CbGpPWpGaD
Etomidate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00158	0.00159	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.00156	0.00157	CbGpPWpGaD
Etomidate—SLC2A1—Disease—TGFBR2—bone cancer	0.00155	0.00156	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—CYP3A4—bone cancer	0.00152	0.00153	CbGpPWpGaD
Etomidate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.00145	0.00146	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00142	0.00143	CbGpPWpGaD
Etomidate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00138	0.00139	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.00138	0.00139	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—NDUFA12—bone cancer	0.00136	0.00137	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—RB1—bone cancer	0.00136	0.00137	CbGpPWpGaD
Etomidate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.00133	0.00134	CbGpPWpGaD
Etomidate—GABRB2—Transmission across Chemical Synapses—BRAF—bone cancer	0.0013	0.00131	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—GSTP1—bone cancer	0.0013	0.00131	CbGpPWpGaD
Etomidate—GABRG2—Transmission across Chemical Synapses—BRAF—bone cancer	0.00119	0.0012	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—SMO—bone cancer	0.00116	0.00117	CbGpPWpGaD
Etomidate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.00116	0.00117	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.00116	0.00116	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—NT5C3A—bone cancer	0.00113	0.00113	CbGpPWpGaD
Etomidate—GABRB2—Transmission across Chemical Synapses—MDM2—bone cancer	0.00109	0.0011	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—GRM4—bone cancer	0.00108	0.00108	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—RGS1—bone cancer	0.00108	0.00108	CbGpPWpGaD
Etomidate—SLC2A1—Disease—KIT—bone cancer	0.00106	0.00106	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—SPARC—bone cancer	0.00104	0.00105	CbGpPWpGaD
Etomidate—GABRA1—Transmission across Chemical Synapses—BRAF—bone cancer	0.00104	0.00105	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—ENO2—bone cancer	0.00101	0.00102	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—JUN—bone cancer	0.00101	0.00101	CbGpPWpGaD
Etomidate—GABRG2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000998	0.001	CbGpPWpGaD
Etomidate—GABRB2—Neuronal System—BRAF—bone cancer	0.000998	0.001	CbGpPWpGaD
Etomidate—SLC2A1—Disease—BRAF—bone cancer	0.000994	0.001	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—GRM4—bone cancer	0.000978	0.000984	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—RGS1—bone cancer	0.000978	0.000984	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—GNA11—bone cancer	0.000952	0.000958	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—DHFR—bone cancer	0.000937	0.000943	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—GRM1—bone cancer	0.000934	0.00094	CbGpPWpGaD
Etomidate—GABRA1—SIDS Susceptibility Pathways—JUN—bone cancer	0.000925	0.000931	CbGpPWpGaD
Etomidate—GABRG2—Neuronal System—BRAF—bone cancer	0.000913	0.000918	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—GNA11—bone cancer	0.000876	0.000881	CbGpPWpGaD
Etomidate—GABRA1—Transmission across Chemical Synapses—MDM2—bone cancer	0.000872	0.000878	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—ENO2—bone cancer	0.00087	0.000876	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—IL3—bone cancer	0.000863	0.000869	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—GRM1—bone cancer	0.000848	0.000854	CbGpPWpGaD
Etomidate—GABRB2—Neuronal System—MDM2—bone cancer	0.000836	0.000841	CbGpPWpGaD
Etomidate—SLC2A1—Disease—MDM2—bone cancer	0.000833	0.000838	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—DHFR—bone cancer	0.000808	0.000813	CbGpPWpGaD
Etomidate—SLC2A1—Disease—PTGS2—bone cancer	0.000803	0.000808	CbGpPWpGaD
Etomidate—GABRA1—Neuronal System—BRAF—bone cancer	0.000798	0.000803	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—CYP3A4—bone cancer	0.000794	0.000799	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.00079	0.000795	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.00079	0.000795	CbGpPWpGaD
Etomidate—GABRG2—Neuronal System—MDM2—bone cancer	0.000765	0.000769	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—GNA11—bone cancer	0.000755	0.000759	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—CYP3A4—bone cancer	0.000684	0.000689	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000681	0.000685	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—GSTP1—bone cancer	0.000679	0.000683	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—PTGS2—bone cancer	0.000673	0.000677	CbGpPWpGaD
Etomidate—GABRA1—Neuronal System—MDM2—bone cancer	0.000668	0.000673	CbGpPWpGaD
Etomidate—CYP19A1—Integrated Breast Cancer Pathway—TP53—bone cancer	0.000664	0.000668	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—GNA11—bone cancer	0.000602	0.000606	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—SMO—bone cancer	0.000598	0.000601	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—GSTP1—bone cancer	0.000585	0.000589	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—GRM4—bone cancer	0.000578	0.000582	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—RGS1—bone cancer	0.000578	0.000582	CbGpPWpGaD
Etomidate—SLC2A1—Disease—EGFR—bone cancer	0.000569	0.000573	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PLAU—bone cancer	0.000566	0.00057	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—GNA11—bone cancer	0.000547	0.00055	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—IL3—bone cancer	0.000546	0.000549	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—GRM1—bone cancer	0.000501	0.000504	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—IL3—bone cancer	0.000496	0.000499	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ENO2—bone cancer	0.000493	0.000496	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—DHFR—bone cancer	0.000458	0.000461	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—GNA11—bone cancer	0.000428	0.00043	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CYP3A4—bone cancer	0.000388	0.00039	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000386	0.000388	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—SMO—bone cancer	0.000353	0.000355	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PTGS2—bone cancer	0.000352	0.000354	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—GSTP1—bone cancer	0.000332	0.000334	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—GNA11—bone cancer	0.000323	0.000325	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PTGS2—bone cancer	0.000303	0.000305	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—ATF1—bone cancer	0.0003	0.000302	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IL3—bone cancer	0.000293	0.000295	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TGFBR2—bone cancer	0.00025	0.000252	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IGF1R—bone cancer	0.000236	0.000237	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—TP53—bone cancer	0.000228	0.000229	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PTGS2—bone cancer	0.000172	0.000173	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—KIT—bone cancer	0.000171	0.000172	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—BRAF—bone cancer	0.000161	0.000162	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—EGFR—bone cancer	0.000156	0.000157	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MDM2—bone cancer	0.000135	0.000135	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—JUN—bone cancer	0.000117	0.000118	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MMP9—bone cancer	0.000114	0.000114	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—EGFR—bone cancer	9.19e-05	9.25e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TP53—bone cancer	7.72e-05	7.77e-05	CbGpPWpGaD
